The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
ESO Guideline on covert cerebral small vessel disease
Open accessAbstract
‘Covert’ cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological manifestations, and increases the risk of future stroke, cognitive impairment, dependency, and death. These European Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist with clinical decisions about management of ccSVD, specifically white matter hyperintensities and lacunes, to prevent adverse clinical outcomes. The guidelines were developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We prioritised the clinical outcomes of stroke, cognitive decline or dementia, dependency, death, mobility and mood disorders, and interventions of blood pressure lowering, antiplatelet drugs, lipid lowering, lifestyle modifications, glucose lowering and conventional treatments for dementia. We systematically reviewed the literature, assessed the evidence, formulated evidence-based recommendations where feasible, and expert consensus statements. We found little direct evidence, mostly of low quality. We recommend patients with ccSVD and hypertension to have their blood pressure well controlled; lower blood pressure targets may reduce ccSVD progression. We do not recommend antiplatelet drugs such as aspirin in ccSVD. We found little evidence on lipid lowering in ccSVD. Smoking cessation is a health priority. We recommend regular exercise which may benefit cognition, and a healthy diet, good sleep habits, avoiding obesity and stress for general health reasons. In ccSVD, we found no evidence for glucose control in the absence of diabetes or for conventional Alzheimer dementia treatments. Randomised controlled trials with clinical endpoints are a priority for ccSVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“We used WMH volume mean and SD, converting medians to means where needed (Figure 5).(96) The standardised mean difference was –0.”
MethodA Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170 · cited 1×
“Rationale for expert consensus statement Guidelines recommend the use of antithrombotic drugs to reduce the risk of recurrent stroke in patients with TIA or minor stroke, and of recurrent MI, MACE and vascular death in patients with prior overt vascular events.(85,86) However, we found no evidence to support the use o…”
Background2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132 · cited 2×
“Based on this and other evidence, some but not all clinical guidelines in recent years have recommended BP targets lower than the standard targets of less than 140/ 90mmHg.(31,32) Indeed, there remains some controversy on the risk/benefit ratio of very low SBP targets.”
BackgroundGorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 1×
“cognitive functioning.(115) A pooled analysis of 322 individuals from two RCTs targeting lifestyle and vascular risk factors with multi-domain interventions to prevent post-stroke cognitive impairment found limited evidence of benefit on attention but not on other cognitive domains.”
BackgroundEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · cited 1×
“the standard (SBP <140mmHg) BP lowering group (although the risk of stroke, a secondary outcome, was significantly reduced), while the risk of adverse events was significantly higher.(34) The association of hypertension and antihypertensive drugs with dementia (PICO 1.”
BackgroundO'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448 · cited 1×
“1) and, because of its high frequency, about half of all strokes are attributable to hypertension.(26) Many clinical trials and meta-analyses have long demonstrated that lowering BP reduces the risk of stroke, coronary heart disease events (in primary and in secondary prevention), and the risk of death.”
Background. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775 · cited 1×
“Many clinical trials and meta-analyses have long demonstrated that lowering BP reduces the risk of stroke, coronary heart disease events (in primary and in secondary prevention), and the risk of death.(27,28) The SPRINT trial showed that among 9361 patients aged 50 years (mean 67.”
BackgroundSmall vessel disease: mechanisms and clinical implications
Wardlaw, J. M., Smith, C., & Dichgans, M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30079-1 · Cited by 1,777
Self-citationWilliamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246 · cited 1×
“11 years).(44) Of note, the ACCORD-MIND trial (N1⁄44733), which used a similar BP target (SBP<120mmHg) in diabetic patients, observed a greater decline in total brain volume (p1⁄40.”
BackgroundMcShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke
The SPS3 Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204133 · Cited by 679
Effect of aspirin on disability-free survival in the healthy elderly
McNeil, J. J., Woods, R. L., Nelson, M. R., Reid, C. M., Kirpach, B., Wolfe, R., Storey, E., Shah, R. C., Lockery, J. E., Tonkin, A. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800722 · Cited by 590 · cited 1×
“11).(77) However, aspirin did increase major haemorrhage (HR 1.”
BackgroundLauner, L. J., Miller, M. E., Williamson, J. D., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M., Horowitz, K. R., Ding, J., Marcovina, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70188-0 · Cited by 574 · cited 3×
“0007).(126) The protective effect of intensive glycaemic control on preserving brain volume was confirmed in later analyses, where however an interaction between BP lowering and glycaemic control on total brain volume was detected.”
BackgroundResultInfluentialHomocysteine lowering interventions for preventing cardiovascular events
Martí-Carvajal, A. J., Solà, I., Lathyris, D., & Salanti, G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006612.pub2 · Cited by 520
Dufouil, C., Chalmers, J., Coskun, O., Besançon, V., Bousser, M.-G., Guillon, P., MacMahon, S., Mazoyer, B., Neal, B., Woodward, M., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.501163 · Cited by 461
Ding, J., Davis-Plourde, K. L., Sedaghat, S., Tully, P. J., Wang, W., Phillips, C., Pase, M. P., Himali, J. J., Gwen Windham, B., Griswold, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30393-x · Cited by 312 · cited 2×
“The most recent and largest Individual Participant Data (IPD) meta-analysis, with the longest follow-up, combined 6 population-based longitudinal cohort studies (n1⁄431090, age >55 years, 7 to 22 years follow-up).(41) This study found that in participants in the highest BP stratum ( 140/90mmHg) using any versus no ant…”
BackgroundSelf-citationMcShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310
Mortensen, M. B., & Nordestgaard, B. G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32233-9 · Cited by 290
Dichgans, M., Markus, H. S., Salloway, S., Verkkoniemi, A., Moline, M., Wang, Q., Posner, H., & Chabriat, H. S. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70046-2 · Cited by 264
Self-citationMemantine for the Treatment of Dementia: A Review on its Current and Future Applications
Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., Garcia, M. L., Olloquequi, J., Casadesús, G., Beas-Zarate, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170672 · Cited by 245 · cited 1×
“Deficits in cholinergic and glutamatergic pathways are involved in cognitive decline in Alzheimer’s disease.(138,139) There is also evidence for cholinergic involvement in VCI.”
BackgroundWilliamson, J. D., Launer, L. J., Bryan, R. N., Coker, L. H., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M. D., Horowitz, K. R., Ding, J., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13656 · Cited by 187
Effect of pravastatin on cerebral infarcts and white matter lesions
ten Dam, V. H., van den Heuvel, D. M. J., van Buchem, M. A., Westendorp, R. G. J., Bollen, E. L. E. M., Ford, I., de Craen, A. J. M., & Blauw, G. J. (2005) · Neurology · doi:10.1212/01.wnl.0000161844.00797.73 · Cited by 113 · cited 1×
“73).(93) Mok et al, in the ROCAS RCT trial substudy,(88) found no effect of simvastatin 20mg daily versus placebo for two years on WMH progression in 208 patients with asymptomatic MCA stenosis and a median age 63 years, but most patients (about 70%) had very few or no WMH at baseline.”
BackgroundWeber, R., Weimar, C., Blatchford, J., Hermansson, K., Wanke, I., Möller-Hartmann, C., Gizewski, E. R., Forsting, M., Demchuk, A. M., Sacco, R. L., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.648576 · Cited by 82
Cited by
Neuroimaging standards for research into small vessel disease—advances since 2013
Duering, M., Biessels, G. J., Brodtmann, A., Chen, C., Cordonnier, C., de Leeuw, F.-E., Debette, S., Frayne, R., Jouvent, E., Rost, N. S., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00131-x · Cited by 1,144
Self-citationCerebral small vessel disease: Recent advances and future directions
Markus, H. S., & de Leeuw, F. E. (2023) · International Journal of Stroke · doi:10.1177/17474930221144911 · Cited by 405
Self-citationBushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Debette, S., Caro, I., Western, D., Namba, S., Sun, N., Kawaguchi, S., He, Y., Fujita, M., Roshchupkin, G., D'Aoust, T., et al. (2024) · doi:10.21203/rs.3.rs-4535534/v1 · Cited by 5
Self-citation
Metadata
- Authors
- Wardlaw, J. M., Debette, S., Jokinen, H., De Leeuw, F.-E., Pantoni, L., Chabriat, H., Staals, J., Doubal, F., Rudilosso, S., Eppinger, S., Schilling, S., Ornello, R., Enzinger, C., Cordonnier, C., Taylor-Rowan, M., & Lindgren, A. G.
- Venue
- European Stroke Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-06-01
- Volume
- 6
- Issue
- 2
- Pages
- CXI-CLXII
- ISSN
- 2396-9873 (ISSN-L)
- 2396-9881
- OpenAlex
- W3161563824
- Cited by
- 168
- References
- 33
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.